Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Study of LY2140023 vs Atypical Antipsychotic Standard of Care in Schizophrenia
KCT0000981Phase 3Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomaglumetad methionil in schizophrenia, sponsored by Eli Lilly and Company. Planned start Jan 2014; status: withdrawn.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on KCT0000981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000981.